Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming
Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...
Inflammation-triggering cellular pathway identified as potential new drug target for Alzheimer's disease
A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers ...
Advanced computational tool reveals cellular development processes
The human body is a key subject of research by scientists worldwide. A biomedical engineering research team led by Professor ...
openaccessgovernment3h
Process intensification: A game changer for the pharma market
Deborah McElhone, Head of Sustainability (Pharma) from CPI, argues that process intensification is a game changer for the ...
Novartis7h
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...